Gapping up
In reaction to strong earnings/guidance: SD +10%, (SandRidge Energy, Inc. Updates Shareholders on Financial Results for Q3), HELE +5.6%, INFY +5.3%, HURC +5%, UMC +3.8%, BOOT +3.6%, BAMM +1.8%, (reports holiday comps for 9 wk period ending 1/3 were +1.2% Y/Y and +1.7% excluding e-Reader devices), AZZ +1.3%
M&A news: RRTS +5.1% hearing M&A speculation as catalyst)
Other news: CERE +37.5% (favorable results from its biotech corn evaluations in China ), AGEN +33.6% (Agenus and and Incyte (INCY) announce a global license, development and commercialization agreement), PTLA +13% (announces Phase 3 ANNEXA-R study of andexanet alfa and factor Xa inhibitor XARELTO met primary endpoint with high statistical significance), RVNC +9.5% (announces publication of positive results from RT002 Phase 1/2 study in which RT002 achieved median duration of 7 mos, met its efficacy and safety endpoints), ARNA +4.2% (confirms in filing that following its data release on the 7th from its Phase 1b trial for APD334), PRTO +3.9% (announced publication of nonclinical data on PRT-201 in peripheral artery disease), BIND +3.5% (cont volatility following yday's move), KBIO +3.1% (CEO David W. Pritchard announced retirement), CY +1.7% (favorable commentary on Thursday's Mad Money), TNXP +1.6% (completed a Phase 1 safety, tolerability, and pharmacokinetic study of TNX-201), GILD +1.4% (seeing reports that health insurer Anthem has selected Harvoni as hepatitis C drug of choice)
Analyst comments: YELP +3.1% (upgraded to Buy from Neutral at BofA/Merrill), CARA +2.7% (initiated with a Buy at Canaccord Genuity), WYNN +2.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley), PGH +2.1% (upgraded to Overweight from Equal Weight at Barclays), KITE +1.7% (initiated with a Buy at Mizuho), FCAU +1.5% (upgraded to Neutral from Underperform at Credit Suisse), GMCR +0.9% (initiated with a Buy at UBS)
In reaction to strong earnings/guidance: SD +10%, (SandRidge Energy, Inc. Updates Shareholders on Financial Results for Q3), HELE +5.6%, INFY +5.3%, HURC +5%, UMC +3.8%, BOOT +3.6%, BAMM +1.8%, (reports holiday comps for 9 wk period ending 1/3 were +1.2% Y/Y and +1.7% excluding e-Reader devices), AZZ +1.3%
M&A news: RRTS +5.1% hearing M&A speculation as catalyst)
Other news: CERE +37.5% (favorable results from its biotech corn evaluations in China ), AGEN +33.6% (Agenus and and Incyte (INCY) announce a global license, development and commercialization agreement), PTLA +13% (announces Phase 3 ANNEXA-R study of andexanet alfa and factor Xa inhibitor XARELTO met primary endpoint with high statistical significance), RVNC +9.5% (announces publication of positive results from RT002 Phase 1/2 study in which RT002 achieved median duration of 7 mos, met its efficacy and safety endpoints), ARNA +4.2% (confirms in filing that following its data release on the 7th from its Phase 1b trial for APD334), PRTO +3.9% (announced publication of nonclinical data on PRT-201 in peripheral artery disease), BIND +3.5% (cont volatility following yday's move), KBIO +3.1% (CEO David W. Pritchard announced retirement), CY +1.7% (favorable commentary on Thursday's Mad Money), TNXP +1.6% (completed a Phase 1 safety, tolerability, and pharmacokinetic study of TNX-201), GILD +1.4% (seeing reports that health insurer Anthem has selected Harvoni as hepatitis C drug of choice)
Analyst comments: YELP +3.1% (upgraded to Buy from Neutral at BofA/Merrill), CARA +2.7% (initiated with a Buy at Canaccord Genuity), WYNN +2.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley), PGH +2.1% (upgraded to Overweight from Equal Weight at Barclays), KITE +1.7% (initiated with a Buy at Mizuho), FCAU +1.5% (upgraded to Neutral from Underperform at Credit Suisse), GMCR +0.9% (initiated with a Buy at UBS)